Lihi Radomir, Matthias P Kramer, Michal Perpinial, Nofar Schottlender, Stav Rabani, Keren David, Anna Wiener, Hadas Lewinsky, Shirly Becker-Herman, Rina Aharoni, Ron Milo, Claudia Mauri, Idit Shachar
Nature communications 2021 Mar 25B cells have essential functions in multiple sclerosis and in its mouse model, experimental autoimmune encephalomyelitis, both as drivers and suppressors of the disease. The suppressive effects are driven by a regulatory B cell (Breg) population that functions, primarily but not exclusively, via the production of IL-10. However, the mechanisms modulating IL-10-producing Breg abundance are poorly understood. Here we identify SLAMF5 for controlling IL-10+ Breg maintenance and function. In EAE, the deficiency of SLAMF5 in B cells causes accumulation of IL10+ Bregs in the central nervous system and periphery. Blocking SLAMF5 in vitro induces both human and mouse IL-10-producing Breg cells and increases their survival with a concomitant increase of a transcription factor, c-Maf. Finally, in vivo SLAMF5 blocking in EAE elevates IL-10+ Breg levels and ameliorates disease severity. Our results suggest that SLAMF5 is a negative moderator of IL-10+ Breg cells, and may serve as a therapeutic target in MS and other autoimmune diseases.
Lihi Radomir, Matthias P Kramer, Michal Perpinial, Nofar Schottlender, Stav Rabani, Keren David, Anna Wiener, Hadas Lewinsky, Shirly Becker-Herman, Rina Aharoni, Ron Milo, Claudia Mauri, Idit Shachar. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5. Nature communications. 2021 Mar 25;12(1):1893
PMID: 33767202
View Full Text